Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATPharm: Pharmacy-based MAT for Opioid Use Disorder
NCT03766893Phase 1Completed
- Sponsor
- Lifespan Biotech
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buprenorphine + naloxone and naltrexone in opioid use disorder (OUD), sponsored by Lifespan Biotech. Primary endpoints: Pharmacists' dispensing of MAT medications at 4 weeks, Pharmacists' monitoring of MAT care at 4 weeks and 2 more. Started Sep 2018; status: completed.
02
Drugs
buprenorphine + naloxonenaltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03766893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766893.